CClinicalTrials.gg
WithdrawnNCT03443154Updated Jun 27, 2018

VF Test for Prediction of Extremely PTB After Cerclage

An observational study in Preterm Birth and Infection, sponsored by Pediatrix. Withdrawn. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-06-27.

Sponsored by Pediatrix · Observational

Why this study was withdrawn
Industry sponsor withdrew financial support as well as the testing equipment.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
0
Ages
18 Years and older
Sex
Female
01

Study summary

The purpose of this research study is to determine if a vaginal fluid (VF) test can predict very early preterm birth in patients who are scheduled to have an exam indicated cerclage for severe cervical shortening.

Prior to participants undergoing a scheduled amniocentesis two swabs to collect vaginal secretions for the VF tests will be done. During the amniocentesis your doctor will remove amniotic fluid as part of the routine clinical care. From that fluid sample, the study will use less than a quarter teaspoon for the amniotic fluid study test (AF test). Data regarding maternal and birth outcomes will be collected by medical record review.

Read the detailed description

The purpose of this research study is to determine if a vaginal fluid (VF) test can predict very early preterm birth in patients who are scheduled to have an exam indicated cerclage for severe cervical shortening.

Prior to participants undergoing a scheduled amniocentesis, an ultrasound will be done to confirm cervical length and dilation. During a separate sterile speculum exam, the physician will use two swabs to collect vaginal secretions for the VF test. During the amniocentesis the doctor will remove approximately 2 teaspoon of amniotic fluid as part of your standard clinical care. From that fluid sample, the study will use less than a quarter teaspoon for a amniotic fluid study test (AF test). Data regarding maternal and birth outcomes will be collected by medical record review.

The vaginal fluid (VF) sample collection will take approximately 15 minutes to do. The total time in the study is about seven and a half months (from the time the patient consents until 4 weeks after delivery). The only study procedure the patient will experience during her study participation is the collection of the vaginal fluid specimens.

02

Conditions studied

  • Preterm Birth
  • Infection

Browse trials for

Keywords

  • Cerclage
  • Preterm birth
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Hospital based patients

Inclusion criteria

  • Participant age 18 years or older
  • Gestational age between 16w0d to 25w6d
  • Singleton fetus with no apparent major anomalies on ultrasound exam
  • Sonographically absent cervical length and/or sterile digital exam of 2cm or greater dilation
  • Exam-indicated cervical cerclage has been recommended by clinician and patient agrees to proceed with cervical cerclage placement
  • Decision has been made by provider to perform pre-cerclage amniocentesis to rule-out infection, with the understanding that cerclage is contraindicated if findings indicate probable or definitive infection, and patient agrees.

Exclusion criteria

Exclusion Criteria:

  • Planned termination of pregnancy
  • Clinical features consistent with placental abruption or chorioamnionitis
  • Need for immediate delivery based on maternal or fetal issues
  • Fetus with ultrasound-determined major congenital anomalies
  • Multiple gestation
  • Rupture of membranes
  • Patient does not give consent to participate in this study
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
0 participants (actual)
Patient registry
No

Interventions

  • Diagnostic testVF-Test

    A vaginal fluid test of interleukin-6 (IL-6) and alphafetoprotein (AFP).

    Also known as: vaginal fluid test.

05

What researchers measure

Primary outcomes

  1. Rate of very preterm birth (PTB)

    Rate of Very PTB (PTB at less than 28 weeks of pregnancy)

    Time frame: Time frame measured on the date of infant was born. We anticipate this time frame to be approximately 20 weeks.

Secondary outcomes

  1. Rate of Delivery within 7 days of cervical cerclage

    Rate of Delivery within 7 days of cervical cerclage placement

    Time frame: Time frame measured from the date the cerclage was placed until 7 days later

  2. Rate of Delivery at later than 34 weeks of pregnancy

    Rate of Delivery at later than 34 weeks of pregnancy (ie. 34 week pregnant until 42 weeks)

    Time frame: Time frame measured from the time the patient reaches 34 weeks 1 day of pregnancy until birth

  3. Rate of a positive VF test results in association with adverse maternal and perinatal outcomes.

    Rate of a positive VF test results in association with adverse maternal and perinatal outcomes. (defined as death or one or more pre-specified morbidities)

    Time frame: Time frame measured from the time of VF test until 28 days after delivery.

  4. Comparison of AF Test and VF Test results in prediction of a positive amniotic fluid culture

    Comparison of amniotic fluid (AF) Test and vaginal fluid (VF) Test results in prediction of a positive amniotic fluid culture

    Time frame: Time frame measured at the time of the amniocentesis

06

Study locations

No study locations are listed for this record.

07

References and documents

Individual participant data

Plan to share: Undecided — Not decided at this time

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03443154
Lead sponsor
Pediatrix
Collaborators
Hologic, Inc.
Responsible party
Sponsor
First posted
Feb 22, 2018
Start date
Jun 2018 (estimated)
Primary completion
Jun 1, 2018
Completion
Jun 1, 2018
Last update
Jun 27, 2018

Study contacts

Jeroen Vanderhoeven, MD
principal investigator · Pediatrix

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion